UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported)
October 21, 2005 (October 19, 2005)
-----------------------------------
PROTALEX, INC.
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
Delaware
- --------------------------------------------------------------------------------
(State or Other Jurisdiction of Incorporation)
000-28385 91-2003490
- --------------------------------------------------------------------------------
(Commission File Number) (IRS Employer Identification No.)
145 Union Square Drive, New Hope, PA 18938
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
215-862-9720
- --------------------------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
- --------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Section 1 - Registrant's Business and Operations
Item 1.01 Entry into a Material Definitive Agreement.
On October 13, 2005, Protalex, Inc. ("Protalex") and PAREXEL
International LLC ("Parexel") entered into a Clinical Study Agreement (the
"Agreement").
Pursuant to the terms of the Agreement, Parexel will conduct a clinical
trial study for Protalex regarding the use of an investigational new drug called
PRTX-100. Protalex does not believe the costs and expenses associated with the
clinical trials should exceed $600,000.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Protalex, Inc.
--------------
(Registrant)
Date: 10/21/2005 /s/ Marc L. Rose
---------- ----------------------------
By: Marc L. Rose
Title: Vice President of Finance,
Chief Financial Officer, Treasurer and
Corporate Secretary